首頁 > 市場調查報告書 > 醫療設備

e保健體外診斷藥物開發人工智能人工智能藥物研發診斷用人工智能

市場調查報告書

商品編碼

2126383

載體介導疾病診斷市場－策略分析與預測（2026-2035）

Vector-Borne Disease Diagnostics Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月07日 | 出版商:

Knowledge Sourcing Intelligence | 英文 171 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計載體介導疾病診斷市場將從 2026 年的 62.1 億美元成長到 2035 年的 146.9 億美元，複合年成長率為 10.0%。

受病原媒介地理分佈範圍擴大、全球媒介傳播疾病負擔日益加重以及迫切需要快速準確地鑑定病原體以指南患者管理和公共衛生措施等因素的推動，媒介傳播疾病診斷市場正經歷著顯著的變革。這一市場演變的特點是，人們日益認知到早期檢測對治療效果和疫情控制至關重要，尤其是在疾病傳播區域擴大和監測計畫日益完善的情況下。快速診斷測試、分子診斷和數位監測平台的融合，使得媒介傳播疾病的檢測更加快速、便利和整合。隨著媒介傳播疾病疫情日益影響以往被認為風險較低的地區，醫療衛生系統和公共衛生機構正在擴大其檢測能力。透過即時檢測平台、多分子檢測和數位疾病監測整合的大量投資，媒介傳播疾病診斷正逐漸成為全球疫情防範和感染疾病控制的關鍵要素。

市場促進因素

全球媒介傳播疾病負擔的日益加重是推動媒介傳播疾病診斷市場發展的主要動力。媒介傳播疾病在流行地區和新興地區都構成了重大的公共衛生挑戰。隨著環境和人口變化影響媒介的分佈，疾病發生率不斷上升。當疫情迅速蔓延時，傳統的監測方法反應遲緩。各國政府正在擴大診斷檢測項目，以加強疾病監測。因此，日益加重的疾病負擔推動了對診斷解決方案的需求，並促進了媒介傳播疾病診斷的持續發展。公共衛生監測計畫的擴展透過擴大檢測覆蓋範圍進一步加速了市場成長。疾病監測依賴準確的診斷訊息，因為需要及時干預來控制疫情。隨著媒介傳播疾病監測成為策略重點，公共衛生機構正在擴大其檢測覆蓋範圍。在高風險地區，診斷手段的匱乏阻礙了疾病追蹤。衛生部門正在投資建設檢查室網路和檢測基礎設施。加強的監測系統正在支持市場擴張。分子診斷技術的引入提高了診斷的準確性和臨床可靠性。由於媒介傳播疾病的症狀常常重疊，因此準確識別病原體仍然至關重要。隨著診斷準確性變得日益重要，醫療機構正在採用分子檢測技術。傳統方法在疾病早期階段可能引入不確定性。實驗室正在採用先進的分子檢測技術來提高臨床可靠性。這一趨勢正在推動對高效能診斷平台的需求。即時檢測的普及提高了分散式檢查能力和市場需求。許多蟲媒傳染病進展迅速，因此及時診斷對治療決策至關重要。隨著醫療系統對分散式檢查能力的需求不斷成長，即時診斷技術的應用也日益廣泛。對集中式實驗室的依賴限制了偏遠地區的檢測機會。製造商正在開發攜帶式且易於使用的檢測解決方案。

市場限制因素

地方性流行區診斷基礎設施的匱乏限制了先進檢測技術的普及。在許多高發地區，偵測設施和設備的不足限制了先進診斷技術的擴充性。分子診斷平台的高成本阻礙了其在資源匱乏的醫療衛生系統中的應用。先進技術所需的大量資金投入是發展中地區的一大障礙。疾病症狀的多樣性使診斷複雜化，也增加了結果解讀的難度。媒介傳播疾病的臨床表現多種多樣，也使得準確診斷面臨挑戰。不同司法管轄區之間法規的複雜性，也為尋求將新型診斷解決方案商業化的製造商帶來了合規性方面的挑戰。

市場定義和範圍
媒介傳播疾病概述
產業變化
主要市場趨勢
疾病負擔與未滿足的診斷需求
發病率和盛行率分析
已確診患者族群的分析
測試數量分析
疾病監測及疫情監測分析
對病人歷程和診斷過程的評估
實際成果值市場規模分析
市場預測分析

第4章市場動態

市場促進因素
市場限制因素
市場機遇
市場挑戰

第5章行業情勢

產業價值鏈分析
定價分析
還款狀態

第6章：創新趨勢

新型診斷技術
產品創新分析
臨床試驗分析
管道分析
技術藍圖
將人工智慧整合到媒介傳播疾病診斷中
照護現場（PoC診斷）創新分析
數位健康與監測的整合

第7章監理情勢

法律規範
核准流程
合規要求

第8章：載體介導疾病診斷市場：展望分析

分析：按技術平台
分析：依生物標記類型
分析：依檢體類型
分析：按適用疾病
分析：透過測試方法

第9章載體介導疾病診斷市場：細分市場分析

依產品類型
- 裝置
- 試劑和試劑盒
- 快速診斷檢測（RDT）
- 軟體和服務
依疾病類型
- 瘧疾
- 登革熱
- 基孔古尼亞
- 茲卡病毒感染疾病
- 萊姆病
- 西尼羅河病毒感染疾病
- 黃熱病
- 其他媒介傳播疾病
透過診斷方法
- 分子診斷
- 血清學檢測
- 快速診斷測試
- 顯微鏡檢查
- 次世代定序（NGS）
最終用戶
- 醫院
- 臨床實驗室
- 公共衛生檢測實驗室
- 學術研究機構
- 其他最終用戶

第10章：媒介傳播疾病診斷市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章：媒介傳播疾病診斷市場：國家分析

美國
加拿大
德國
英國
法國
印度
中國
日本
澳洲
巴西
墨西哥
印尼
泰國
沙烏地阿拉伯
南非

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
新產品發布

第13章：公司簡介

Abbott Laboratories
F. Hoffmann-La Roche Ltd.
Danaher Corporation
bioMerieux SA
QIAGEN NV
Thermo Fisher Scientific Inc.
Bio-Rad Laboratories, Inc.
Siemens Healthineers AG
Sysmex Corporation
Hologic, Inc.
Revvity, Inc.
SD Biosensor, Inc.
Chembio Diagnostics, Inc.
OraSure Technologies, Inc.
Genetic Signatures Limited

第14章：載體介導疾病診斷市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009095

The Vector-Borne Disease Diagnostics Market is anticipated to grow at a CAGR of 10.0% from USD 6.21 billion in 2026 to USD 14.69 billion in 2035.

The vector-borne disease diagnostics market is undergoing significant transformation driven by the expanding geographic reach of disease vectors, the rising global burden of vector-borne illnesses, and the critical need for rapid, accurate pathogen identification to guide patient management and public health interventions. The market's evolution is characterized by the growing recognition that early detection influences treatment outcomes and outbreak control, particularly as disease transmission zones expand and surveillance programs become more comprehensive. The convergence of rapid diagnostic tests, molecular diagnostics, and digital surveillance platforms is enabling faster, more accessible, and increasingly integrated vector-borne disease detection. Healthcare systems and public health agencies are expanding testing capabilities as vector-borne outbreaks increasingly affect regions previously considered low risk. The market is witnessing significant investment in point-of-care platforms, multiplex molecular assays, and digital disease surveillance integration, positioning vector-borne disease diagnostics as a critical component of global epidemic preparedness and infectious disease management.

Market Drivers

The rising global burden of vector-borne diseases represents the primary driver for the vector-borne disease diagnostics market. Vector-borne diseases represent a substantial public health challenge across endemic and emerging regions. Disease incidence is increasing as environmental and demographic changes influence vector distribution. Traditional surveillance approaches create response delays when outbreaks spread rapidly. Governments are expanding diagnostic testing programs to strengthen disease monitoring. Growing disease burden therefore increases demand for diagnostic solutions, resulting in sustained growth in vector-borne disease diagnostic utilization. The expansion of public health surveillance programs is further accelerating market growth through increased testing coverage. Disease surveillance depends on accurate diagnostic information because outbreak management requires timely intervention. Public health agencies are increasing testing coverage as vector-borne disease monitoring becomes a strategic priority. Limited diagnostic access constrains disease tracking in high-risk regions. Healthcare authorities are investing in laboratory networks and testing infrastructure. Enhanced surveillance supports market expansion. The adoption of molecular diagnostics is improving diagnostic precision and clinical confidence. Accurate pathogen identification remains essential because symptoms frequently overlap across vector-borne diseases. Healthcare providers are adopting molecular testing technologies as diagnostic precision becomes increasingly important. Conventional methods may create uncertainty during early disease stages. Laboratories are implementing advanced molecular assays to improve clinical confidence. This trend strengthens demand for high-performance diagnostic platforms. Growth in point-of-care testing is expanding decentralized testing capabilities and market demand. Timely diagnosis influences treatment decisions because many vector-borne diseases progress rapidly. Point-of-care diagnostics are gaining adoption as healthcare systems seek decentralized testing capabilities. Centralized laboratory dependence limits access in remote regions. Manufacturers are developing portable and user-friendly testing solutions.

Market Restraints

Limited diagnostic infrastructure in endemic regions restricts access to advanced testing technologies. The lack of adequate laboratory facilities and equipment in many high-burden regions limits the scalability of advanced diagnostics. High costs associated with molecular diagnostic platforms constrain adoption in resource-limited healthcare systems. The significant financial investment required for advanced technologies creates barriers for developing regions. Variability in disease presentation creates diagnostic complexity and increases interpretation challenges. The diverse clinical manifestations of vector-borne diseases can complicate accurate diagnosis. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new diagnostic solutions.

Technology and Product Insights

The technology landscape is characterized by the growing importance of integrated diagnostic ecosystems combining rapid testing, molecular platforms, and digital surveillance. Rapid diagnostic tests represent a major demand segment because they support immediate decision-making in endemic and resource-limited regions. Testing volumes are increasing as public health agencies expand surveillance coverage. Molecular diagnostics adoption is increasing because healthcare providers require greater diagnostic precision. Serological testing continues supporting surveillance and epidemiological investigations. Microscopy-based testing remains important in malaria-endemic regions. NGS technologies are emerging for advanced surveillance and outbreak characterization. The segment analysis reveals that malaria remains a major diagnostic category because endemic regions require continuous testing programs. Dengue fever testing demand is increasing as outbreaks affect larger populations across tropical and subtropical regions. Lyme disease testing remains significant in developed markets where tick-borne diseases continue expanding geographically. Rapid diagnostic testing remains widely utilized because it supports decentralized disease management. Molecular diagnostics adoption is increasing because healthcare providers require greater diagnostic precision. Public health laboratories represent a critical end-user segment, with hospitals and clinical laboratories expanding testing capabilities. The integration of digital surveillance is becoming increasingly important because outbreak monitoring depends on real-time data collection and analysis. Technology providers are introducing connected diagnostic platforms.

Competitive and Strategic Outlook

The competitive landscape features established diagnostics and life science companies alongside specialized rapid test, molecular, and public health providers. Abbott remains strategically distinct because it combines extensive infectious disease expertise with a strong rapid diagnostics portfolio, benefiting from global healthcare reach and established relationships with public health organizations. Roche leverages molecular diagnostics leadership to support infectious disease detection, focusing on automation, scalability, and analytical performance. Danaher participates through multiple diagnostic businesses supporting infectious disease testing, with technological diversity and strong innovation capabilities enhancing market relevance. bioMerieux maintains a strong position in infectious disease diagnostics through microbiology and molecular testing expertise, supporting surveillance and laboratory-based testing workflows. QIAGEN differentiates itself through molecular testing and sample preparation capabilities, continuing to expand infectious disease assay offerings. Thermo Fisher benefits from broad laboratory and molecular diagnostics capabilities, supporting disease surveillance and pathogen identification through extensive technology offerings. Bio-Rad provides molecular diagnostic technologies and laboratory solutions supporting infectious disease management. Siemens Healthineers leverages extensive diagnostic infrastructure and healthcare technology expertise. Companies are pursuing product portfolio expansion through innovation in multiplex molecular assays, rapid diagnostic tests, and digital surveillance platforms. Strategic collaborations between diagnostic manufacturers, public health agencies, and research institutions are increasing, driven by the need for outbreak preparedness and surveillance. Recent key developments include the Serum Institute of India and DNDi signing a licensing agreement covering clinical testing and future access for an SII-developed monoclonal antibody treatment against dengue. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific, Africa, and Latin American markets where vector-borne disease burden is highest.

Short Conclusion

The vector-borne disease diagnostics market is positioned for sustained growth driven by the convergence of disease burden, surveillance expansion, and technological innovation. The transition from centralized laboratory testing toward integrated rapid and molecular diagnostic ecosystems represents a fundamental shift in infectious disease management. While challenges related to infrastructure limitations, high costs, and diagnostic complexity persist, strategic investments in technology, partnerships, and surveillance integration are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with vector-borne disease diagnostics evolving into a critical component of global epidemic preparedness, supporting rapid detection, surveillance, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Vector-Borne Disease Diagnostics Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Overview of Vector-Borne Diseases
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Disease Burden & Unmet Diagnostic Needs
3.6 Epidemiology and Prevalence Analysis
3.7 Diagnosed Patient Population Analysis
3.8 Testing Volume Analysis
3.9 Disease Surveillance and Outbreak Monitoring Analysis
3.10 Patient Journey and Diagnostic Pathway Assessment
3.11 Historical Market Size Analysis (2021-2025)
3.12 Market Forecast Analysis (2026-2035)

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Diagnostic Technologies
6.2 Product Innovation Analysis
6.3 Clinical Trial Analysis
6.4 Pipeline Analysis
6.5 Technology Roadmap
6.6 AI Integration in Vector-Borne Disease Diagnostics
6.7 Point-of-Care Diagnostic Innovation Analysis
6.8 Digital Health and Surveillance Integration

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Vector-Borne Disease Diagnostics Market Landscape Analysis

8.1 Analysis by Technology Platform
8.2 Analysis by Biomarker Type
8.3 Analysis by Sample Type
8.4 Analysis by Disease Application
8.5 Analysis by Testing Methodology

9. Vector-Borne Disease Diagnostics Market Segment Analysis (2021-2035)

9.1 By Product Type
- 9.1.1 Instruments
- 9.1.2 Reagents & Kits
- 9.1.3 Rapid Diagnostic Tests (RDTs)
- 9.1.4 Software & Services
9.2 By Disease Type
- 9.2.1 Malaria
- 9.2.2 Dengue Fever
- 9.2.3 Chikungunya
- 9.2.4 Zika Virus Disease
- 9.2.5 Lyme Disease
- 9.2.6 West Nile Virus Infection
- 9.2.7 Yellow Fever
- 9.2.8 Other Vector-Borne Diseases
9.3 By Diagnostic Method
- 9.3.1 Molecular Diagnostics
- 9.3.2 Serological Testing
- 9.3.3 Rapid Diagnostic Testing
- 9.3.4 Microscopy-Based Testing
- 9.3.5 Next-Generation Sequencing (NGS)
9.4 By End User
- 9.4.1 Hospitals
- 9.4.2 Clinical Laboratories
- 9.4.3 Public Health Laboratories
- 9.4.4 Academic & Research Institutes
- 9.4.5 Other End Users